60929-91-1

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 4696-76-8 kananmycin B 
• 119793-45-2 3',4',2'',4'',6''-penta-O-acetyl-5-O-benzoyl-5-epi-1,3,2',6',3''-penta-N-tosylkanamycin B 

Downstream Products

• 119783-85-6 3',4',2'',4'',6''-penta-O-acetyl-1,3,2',6',3''-penta-N-tosylkanamycin B 
• 144788-47-6 5-Deoxy-5-fluorokanamycin B 0.4 carbonate 
• 119793-47-4 3',4',2'',4'',6''-penta-O-acetyl-5-deoxy-5-fluoro-1,3,2',6',3''-penta-N-tosylkanamycin B 
• 119783-85-6 3',4',2'',4'',6''-penta-O-acetyl-5-epi-1,3,2',6',3''-penta-N-tosylkanamycin B 

Relevant academic research and scientific papers

Preparation method of aminoglycoside drug intermediate

The invention discloses a preparation method of an aminoglycoside drug intermediate. The intermediate is 1, 3, 2', 6', 3''-penta-N-tosyl kanamycin B. The preparation method comprises the following steps: adding kanamycin B, an acid-binding agent and a mixed solvent into a reaction kettle, adding paratoluensulfonyl chloride at 0-30 DEG C, and stirring and reacting for 8-18 hours at 0-30 DEG C; andadding an inert solvent, stirring for 1-24 hours, crystallizing, performing suction filtration, and drying to obtain 1, 3, 2', 6', 3''-penta-N-tosyl kanamycin B. According to the preparation method disclosed by the invention, Ts is used as a protective group, three or more solvents are used as reaction solvents, the reaction conditions are mild, the safety coefficient is high, the yield of the obtained product can reach 90% or higher, and the purity can reach 95% or higher.

Synthesis of 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of kanamycin B and its analogs. Study on structure-toxicity relationships

5-Deoxy-5-fluoro- (1), 5,3'-dideoxy-5-fluoro- (2), and 5,3',4'-trideoxy-5-fluoro-kanamycin B (3) have been prepared by treatment of 5-epihydroxyl precursors (prepared by the Mitsunobu reaction) with DAST as the key step. 5,3'-Dideoxy-5,5-difluoro- (26) an

A synthesis of 3',4'-dideoxykanamycin B.

3',4',-Dideoxykanamycin B, the kanamycin B derivative that is active against resistant bacteria, was prepared from kanamycin B via N-tosylation, 3',4'-O-sulphonylation, 3',4'-unsaturation, and hydrogenation. The unsaturated intermediate was obtained from the 3',4'-di-O-sulphonyl derivatives by the action of sodium iodide in N,N-dimethylformamide; if zinc dust was added in this reaction, aziridine derivatives were formed. Removal of the tosyl group was successfully performed by using sodium in ammonia-ethylamine.